Therapeutic drug monitoring of targeted anticancer therapy

Biomarkers in Medicine
Laurent A DecosterdChantal Csajka

Abstract

New oral targeted anticancer therapies are revolutionizing cancer treatment by transforming previously deadly malignancies into chronically manageable conditions. Nevertheless, drug resistance, persistence of cancer stem cells, and adverse drug effects still limit their ability to stabilize or cure malignant diseases in the long term. Response to targeted anticancer therapy is influenced by tumor genetics and by variability in drug concentrations. However, despite a significant inter-patient pharmacokinetic variability, targeted anticancer drugs are essentially licensed at fixed doses. Their therapeutic use could however be optimized by individualization of their dosage, based on blood concentration measurements via the therapeutic drug monitoring (TDM). TDM can increase the probability of therapeutic responses to targeted anticancer therapies, and would help minimize the risk of major adverse reactions.

References

Nov 19, 2004·Nature·Charles Sawyers
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sae-Won HanNoe Kyeong Kim
Jul 18, 2006·British Journal of Clinical Pharmacology·N WidmerT Buclin
Dec 7, 2006·Journal of the National Cancer Institute·Jing LiSharyn D Baker
Dec 11, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Craig Jordan
Feb 8, 2008·Blood·Richard A LarsonUNKNOWN IRIS (International Randomized Interferon vs STI571) Study Group
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George D DemetriMargaret von Mehren
Jun 10, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·A HaoualaL A Decosterd
Jan 9, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Diane R Mould, Bruce Green
Jan 16, 2010·Leukemia Research·N WidmerL A Decosterd
Jan 26, 2010·Cellular Signalling·Georgios GiamasUwe Knippschild
Feb 25, 2010·British Journal of Cancer·N WidmerT Buclin
Jul 24, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yoichi NakamuraShigeru Kohno
Sep 14, 2010·Cancer Treatment Reviews·Heinz-Josef KlümpenHoward Gurney
Nov 26, 2010·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·E DahmaneL A Decosterd
Nov 30, 2010·The Lancet Oncology·Thierry BuclinLaurent A Decosterd
Jun 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melanie White-KoningGilles Vassal
Oct 19, 2011·Investigational New Drugs·Marilyne HorneckerMichel Tod
Mar 1, 2012·British Journal of Clinical Pharmacology·Thierry BuclinJeffrey Aronson
May 16, 2012·Therapeutic Drug Monitoring·Mohamed SaleemJennifer H Martin
Jul 4, 2012·The Oncologist·Pascaline Boudou-RouquetteFrançois Goldwasser
Aug 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bo GaoHoward Gurney
Sep 18, 2013·Critical Reviews in Oncology/hematology·Audrey Thomas-SchoemannFrançois Goldwasser
Jun 1, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christophe BardinJos Beijnen
Jun 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicolas WidmerAlain Astier

❮ Previous
Next ❯

Citations

Feb 16, 2018·Clinical Pharmacology and Therapeutics·Neeraj GuptaKarthik Venkatakrishnan
Sep 19, 2017·Journal of Clinical Pharmacology·Catherine J Lucas, Jennifer H Martin
Oct 1, 2019·Therapeutic Drug Monitoring·Claire E Knezevic, William Clarke
Mar 21, 2020·Frontiers in Pharmacology·Thierry BuclinLaurent A Decosterd
Jun 20, 2020·Clinical Pharmacology and Therapeutics·Florent FerrerJoseph Ciccolini
Nov 10, 2020·European Journal of Clinical Pharmacology·Anna Mueller-SchoellCharlotte Kloft

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
María Isabel SáezEmilio Alba
© 2021 Meta ULC. All rights reserved